Nara, Japan

Hiroshi Onoue


Average Co-Inventor Count = 3.5

ph-index = 4

Forward Citations = 76(Granted Patents)


Location History:

  • Osaka, JP (1979 - 1986)
  • Nara, JP (1985 - 1992)

Company Filing History:


Years Active: 1979-1992

Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Hiroshi Onoue

Introduction

Hiroshi Onoue is a prominent inventor based in Nara, Japan. He has made significant contributions to the field of antibacterial agents, holding a total of six patents. His work focuses on developing novel compounds that combat bacterial infections, showcasing his dedication to advancing medical science.

Latest Patents

Onoue's latest patents include groundbreaking formulations such as Piperaziniocephalosporins and Phenacylpyridiniothiocephalosporins. The Piperaziniocephalosporins patent details an antibacterial preparation that includes a complex formula designed to kill bacteria and prevent or treat bacterial infections. This patent outlines various components, including hydroxyarylpiperazinocephalosporins and methods for synthesizing these cephalosporins. The Phenacylpyridiniothiocephalosporins patent describes an antibacterial compound and its salts, providing methods for disinfecting and treating bacterial infections.

Career Highlights

Hiroshi Onoue is currently associated with Shionogi & Company Limited, where he continues to innovate in the field of pharmaceuticals. His work has not only contributed to the company's portfolio but has also had a significant impact on public health through the development of effective antibacterial agents.

Collaborations

Onoue has collaborated with notable colleagues such as Masayuki Narisada and Teruji Tsuji. These partnerships have fostered a collaborative environment that enhances the research and development of new antibacterial solutions.

Conclusion

Hiroshi Onoue's contributions to antibacterial research and his innovative patents reflect his commitment to improving healthcare. His work at Shionogi & Company Limited continues to pave the way for advancements in the treatment of bacterial infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…